Values First Advisors Inc. Has $278,000 Position in Boston Scientific Co. (NYSE:BSX)

Values First Advisors Inc. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 817.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,110 shares of the medical equipment provider’s stock after purchasing an additional 2,771 shares during the period. Values First Advisors Inc.’s holdings in Boston Scientific were worth $278,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. Creative Planning grew its holdings in Boston Scientific by 7.7% during the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock worth $17,113,000 after acquiring an additional 14,663 shares during the last quarter. NBC Securities Inc. lifted its position in shares of Boston Scientific by 20.5% during the third quarter. NBC Securities Inc. now owns 11,761 shares of the medical equipment provider’s stock worth $985,000 after purchasing an additional 2,001 shares in the last quarter. Swedbank AB grew its stake in shares of Boston Scientific by 0.6% during the third quarter. Swedbank AB now owns 1,430,925 shares of the medical equipment provider’s stock valued at $119,912,000 after purchasing an additional 8,246 shares during the last quarter. Wolff Wiese Magana LLC increased its holdings in shares of Boston Scientific by 7,262.5% in the third quarter. Wolff Wiese Magana LLC now owns 2,945 shares of the medical equipment provider’s stock valued at $247,000 after purchasing an additional 2,905 shares in the last quarter. Finally, AAFMAA Wealth Management & Trust LLC raised its position in Boston Scientific by 10.4% in the 3rd quarter. AAFMAA Wealth Management & Trust LLC now owns 32,732 shares of the medical equipment provider’s stock worth $2,743,000 after purchasing an additional 3,077 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.2 %

Shares of Boston Scientific stock opened at $105.80 on Thursday. Boston Scientific Co. has a 1 year low of $64.54 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The company has a market capitalization of $155.93 billion, a P/E ratio of 84.64, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The business has a 50-day moving average of $95.50 and a two-hundred day moving average of $87.72.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities analysts predict that Boston Scientific Co. will post 2.83 EPS for the current year.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the completion of the transaction, the director now directly owns 24,398 shares of the company’s stock, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,830 shares of company stock worth $6,415,729 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Bank of America increased their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Morgan Stanley raised their price target on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Mizuho boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. TD Cowen raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company boosted their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.